Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy-Reference-Cited by-同舟云学术

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

Published:2021-03 Issue:2 Volume:22 Page:e180-e192
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Mountzios Giannis,de Toma Alessandro,Economopoulou Panagiota,Friedlaender Alex,Banini Marco,Lo Russo Giuseppe,Baxevanos Panagiotis,Roila Fausto,Banna Giuseppe Luigi,Christopoulou Athina,Jimenez Beatriz,Collazo-Lorduy Ana,Linardou Helena,Calles Antonio,Galetta Domenico,Addeo Alfredo,Camerini Andrea,Pizzutilo Pamela,Kosmidis Paris,Garassino Marina Chiara,Proto Claudia,Signorelli Diego,Metro Giulio

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. The emerging treatment landscape of advanced non-small cell lung cancer;Economopoulou;Ann Transl Med,2018

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24

2. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study);Cancers;2024-05-08

3. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed;European Journal of Cancer;2024-05

4. Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials;Translational Lung Cancer Research;2024-01

5. Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: a pooled analysis of individual patient data from three randomized trials;Cancer Communications;2023-12-25